Companies/Kiora Pharmaceuticals, Inc.

Company profile

Kiora Pharmaceuticals, Inc.

NASDAQ: KPRX · Healthcare · Biotechnology

PublicHQ Encinitas, UTCIK 0001372514Reports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

52D

FH 49DQ 59GM 50SS 43

v0.1 · 65/100 weight · provisional

↑ growth stability, filing timeliness · ↓ revenue growth (YoY), workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$10.8M

Employees

Market cap

$11.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$10.8M-$10.8M2025

Operating income-$12.8M-$12.8M2025

Total assets$24.3M$24.3M2025

Liabilities$8.1M$8.1M2025

Equity$16.1M$16.1M2025

Revenue trend

FY2018 – FY2025 · USD

$407.5k

FY18

$1.7M

FY19

$2.7M

FY19

$12.1k

FY20

FY21

FY24

$16.0M

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Kiora Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

VolitionRX Ltd38D Phio Pharmaceuticals Corp.40D Lexaria Bioscience Corp.43D VYNE Therapeutics Inc.38D

Key facts

CEOBrian Strem

SectorHealthcare

IndustryBiotechnology

HeadquartersEncinitas, UT

ExchangeNASDAQ: KPRX

Employees12

IPO date2015-02-13

Latest filings

8-K2026-06-18 8-K2026-06-11 8-K2026-05-08 10-Q2026-05-08 DEF 14A2026-04-30 8-K2026-04-07 8-K2026-04-02 8-K2026-03-25

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.